AstraZeneca India gets CDSCO approval for additional indication for Osimertinib in unresectable EGFR-mutated lung cancer Read more
Alembic gains USFDA final approval for Amlodipine & Atorvastatin Tablets USP, 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, & 10 mg/80 mg Read more
AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low breast cancer in India Read more